|1.||Jiang, Chuantao: 1 article (03/2004)|
|2.||Christian, Samuel T: 1 article (03/2004)|
|3.||Sundsmo, John S: 1 article (03/2004)|
|4.||Le, Weidong: 1 article (03/2004)|
|5.||Jankovic, Joseph: 1 article (03/2004)|
|6.||Pristupa, Zdenek B: 1 article (03/2004)|
|7.||Niznik, Hyman B: 1 article (03/2004)|
|8.||Wan, Xinhua: 1 article (03/2004)|
|1.||Parkinson Disease (Parkinson's Disease)
03/01/2004 - "Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease."
03/01/2004 - "IPX-750 was evaluated in the Parkinson's disease animal models, including MPTP mouse model, the 6-hydroxydopamine (6-OHDA) rat model and the Nurr1(+/-) knockout mouse model. "
|2.||Deficiency Diseases (Deficiency Disease)
03/01/2004 - "These combined results suggest (i) that stereo-specific glycoconjugation may be an effective method to improve penetrability of drugs through the blood brain barrier; (ii) treatment with bioavailable IPX-750 in vitro did not show evidence for neurotoxicity; and, (iii) IPX-750 possesses dopaminergic properties and exerts anti-parkinsonian effects in three different PD rodent models, suggesting therapeutic potential for this new class of drugs in treating dopamine deficiency diseases."
|1.||Oxidopamine (6 Hydroxydopamine)
|2.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)